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Available online 12 March 2014Abstract In the present study, we investigated the effect of simultaneous downregulation of uPAR and cathepsin B (pUC), alone
or in combination with radiation, on JNK–MAPK signaling pathway in regulating the migration of non-GICs (glioma-initiating cells)
and GICs. The increase in the expression of p-JNK with pUC treatment was mostly localized to nucleus whereas increase in the
expression of p-JNK with radiation and overexpression of uPAR and cathepsin B was confined to cytoplasm of the cells. Depletion of
cytosolic p-JNK with pUC treatment inhibited migration by downregulating the expression of the adapter proteins of the focal
adhesion complex. We also observed that knockdown of uPAR and cathepsin B regulated the Ras–Pak-1 pathway to induce the
translocation of p-JNK from cytosol to nucleus. In control cells, Pak-1 served as a functional inhibitor for MEKK-1, which inhibits the
complex formation of MEKK-1 and p-JNK and thus inhibits the translocation of this complex into nucleus. Hence, we conclude that
glioma cells utilize the availability of cytosolic p-JNK in driving the cells towards migration. Finally, treating the cells with pUC
alone or in combination with radiation induced the translocation of the MEKK-1-p-JNK complex from cytosol to nucleus, thereby
inhibiting the migration of glioma cells.
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(http://creativecommons.org/licenses/by-nc-nd/3.0/).Treatment for glioblastoma multiforme (GBM), the most
lethal primary brain tumor, remains essentially palliative
despite multimodal therapies including surgical resection,
radiation and chemotherapy (Inoue et al., 2010). Aggressive
infiltration of GBM cancer cells into normal brain tissue
often prevents the complete removal of tumor cells through
surgical resection. In addition, the existence of a small
subpopulation of glioma cells that escapes radiation and
chemotherapy-induced cell death makes GBM currently
incurable (Gilbert and Ross, 2009). These small subpopulationess article under the CC BY-NC-ND license
717Compartmentalization of JNK Regulates Glioma Migrationof cells, referred to as glioma stem cells or glioma-initiating
cells (GICs), have been shown to be highly tumorigenic, highly
invasive, pro-angiogenic and resistant to therapy compared
with the majority of tumor cells, suggesting the importance of
targeting GICs when developing novel glioma therapies
(Hjelmeland et al., 2011).
In solid malignancies, it is unusual for a single kinase
abnormality or only one abnormally activated signaling path-
way to be the sole cause of disease. Instead multiple signaling
pathways or even a single molecular event with multiple
downstream effects are dysregulated (Gossage and Eisen,
2010). One of themost exquisite examples includes themitogen
activated pathway kinases (MAPKs), which transduce signals
that are involved in a multitude of cellular pathways and
functions based on the cues derived from cell surface,
metabolic state and environment of the cell (Lawrence et al.,
2008; Owens and Keyse, 2007). Abnormalities in MAPK signaling
impinge on most of the hallmark characteristics required for
the development and progression of cancer (Dhillon et al.,
2007). Therefore, targeting a key underlying defect in theMAPK
signaling may provide a greater potential for increased efficacy
by simultaneous inhibition of multiple pathways.
The c-Jun NH2-terminus kinases (JNKs) belong to the
MAPK family, which also includes the extracellular signal-
regulated kinase (ERK) and p38 mitogen-activated protein
kinase. JNKs are activated in response to inflammatory
cytokines; environmental stresses, such as heat shock, ionizing
radiation, oxidant stress and DNA damage; DNA and protein
synthesis inhibition; and growth factors (Raman et al., 2007).
One of the most extensively studied and well-known functions
of JNK is its induction of apoptosis. Upon activation, the
phosphorylated JNK translocates to nucleus where it phos-
phorylates and regulates the activation of transcription factors
like c-Jun, ATF-2, Elk-1, p53 and c-Myc, which are involved in
the induction of cell apoptosis (Dhanasekaran and Reddy,
2008; Johnson and Nakamura, 2007; Wang et al., 2010).
However, it has been recently reported that the inhibition
of JNK activity impairs cell migration of fibroblasts, smooth
muscle cells, keratinocytes, rat bladder tumor cells, endothe-
lial cells and Schwann cells (Chen et al., 2009; Huang et al.,
2004b). In addition, JNK phosphorylates Paxillin on Ser178 and
regulates the migration of NBT-II cells, MDA-MB-231 breast
cancer cells and Chinese hamster ovary cells (Huang et al.,
2003, 2004a, 2008). These findings emphasize the fact that the
activation of JNK might be critical for the migration of cells.
Proteolytic enzymes and proteases are necessary for the
degradation of surrounding proteins and other tissue
components and thus play crucial roles in multiple steps of
cancer invasion and metastasis (Edwards and Cancer, 1998).
Among the proteases, uPAR and cathepsin B are often
detected in higher amounts in malignant tumors and have
been attributed to contribute major roles in the cancer
progression (Alapati et al., 2012; Malla et al., 2012a;
Mohamed and Sloane, 2006; Rao, 2003; Smith and
Marshall, 2010). Earlier reports indicate that the blockade
of uPAR and cathepsin B expression induced a significant
reduction in the migration and invasion capabilities of
cancer cells (Ahmed et al., 2003; Matarrese et al., 2010;
Nalla et al., 2010; Veeravalli et al., 2010; Victor et al.,
2011) by effectively abrogating the activation of MAPK
signaling (Rabbani et al., 2010; Wegiel et al., 2009; Wu et
al., 2008).In the present study, we studied the effect of shRNA-
mediated downregulation of uPAR and cathepsin B (pUC)
on 5310 and 4910 non-GICs and GICs either alone or in
combination with radiation treatment. Our findings indicate
that treating non-GICs and GICs with pUC alone or in
combination with radiation reduced the migration of these
cells by regulating the JNK–MAPK signaling through the
Ras-PI3K pathway in vitro and in vivo. We also observed that
a major pool of p-JNK accumulated in the cytoplasm of
untreated or irradiated glioma cells while the activated JNK
translocated into the nucleus of the non-GICs and GICs
treated with pUC alone and in combination with radiation.
Further, cytoplasmic p-JNK interacted with adapter proteins
of the focal adhesion complex and drove the cells towards an
aggressive migratory phenotype.Materials & methods
Ethics statement
The Institutional Animal Care and Use Committee of the
University of Illinois College of Medicine at Peoria (Peoria,
IL) approved all surgical interventions and post-operative
animal care. The consent was written and approved. The
approved protocol number is 851 and is dated November 20,
2009.Cell culture conditions
5310 and 4910 glioma xenograft cells kindly provided by Dr.
David James (University of California—San Francisco, San
Francisco, CA) were cultured in RPMI 1640 medium supple-
mented with 10% FBS and 1% penicillin/streptomycin. Cells
were kept at 37 °C in a humidified incubator with 5% CO2. 5310
and 4910 GICs and non-GICs were isolated with PE-conjugated
CD133 antibody and cultured in their respective media as
described earlier (Alapati et al., 2012; Malla et al., 2012a).Transfection, radiation and inhibitor treatments
All transfections were carried out in 100-mm culture plates
using X-tremeGENE 9 reagent as per the manufacturer's
protocol (Roche, Indianapolis, IN). 5310 and 4910 non-GICs
and GICs were transfected with scrambled vector (pSV) or a
bicistronic shRNA construct of uPAR and cathepsin B (pUC).
Either at 48 h (non-GIC) or at 24 h (GIC) after transfection,
the cells were treated with 10 Gy using an RS 2000 biological
irradiator (Rad Source Technologies Inc., Boca Raton, FL) X-ray
unit operated at 150 kV/25 mA. Cells were then incubated
for another 24 h or 48 h, respectively. Cells were transfected
with a plasmid expressing full-length human cDNA clone of
uPAR (FLU) (SC319092, Origene, Rockville, MD) and cathepsin
B (FLC) (SC109129, Origene, Rockville, MD) for uPAR and
cathepsin B overexpression studies. For inhibitor studies, cells
seeded in six-well plates were treated with U0126 (10 μM,
Promega, Madison, WI), SP600125 (10 μM, EMD Millipore,
Billerica, MA), SB202190 (10 μM, Sigma, St. Louis, MO), or
IPA3 (10 μM, SCBT, Santa Cruz, CA) for 24 h.
718 K. Alapati et al.Immunoblotting and immunoprecipitation
Total protein (40 μg) was separated by 10% SDS-PAGE and
transferred to a nitrocellulose membrane. The membrane
was then blocked with 5% non-fat milk for 1 h, incubated
with primary antibody overnight at 4 °C, washed thrice with
PBS-T (PBS plus 0.1% Tween 20), and incubated with HRP-
linked secondary antibody for 1 h at room temperature. The
membrane was then washed and bands were visualized by
chemiluminescence assay. The following antibodies were
used: uPAR, cathepsin B, ERK, p-ERK, JNK, p-JNK, p38, p-p38,
Vinculin,α-Actinin, Talin, PI3K, p-PI3K, Rac-1, MEKK-1, Laminin
and GAPDH (all from SCBT, Santa Cruz, CA). We also used
antibodies for Paxillin, p-Paxillin, Pak-1 and p-Pak-1 (all from
Cell Signaling Technology, Danvers, MA). We obtained Ras10
from Millipore (Billerica, MA).
For immunoprecipitation, cell lysates (300 μg) were
pre-cleared by protein A/G micro-beads (Miltenyi Biotec,
Auburn, CA) and then incubated with specific antibodies
at a dilution of 1:100 overnight at 4 °C. The beads were
washed with lysis buffer and resuspended in sample buffer
before the immunoprecipitated protein was subjected to
immunoblotting.Spheroid migration assay
5310 and 4910 non-GIC and GIC spheroids were prepared in
96-well plates coated with 1% agar by seeding 3 × 104 cells/
well. The plates were then incubated on a shaker at 100 rpm
for 24 h in a humidified chamber at 37 °C with 5% CO2. The
spheroids were treated with SV, pUC, 10 Gy, pUC + 10 Gy,
FLU, FLC, U0126, SP600125 or SB202190 for specific time
points and then transferred to 24-well plates and allowed to
migrate for another 24 h. Spheroids were then fixed and
stained with Hema-3, and cell migration was assessed using a
light microscope. The migration of cells from spheroids to
monolayers was used as an index of cell migration and was
measured using a microscope calibrated with a stage and
ocular micrometer. Statistical comparisons were performed
using GraphPad Prism software (version 3.02). Quantitative
data from migration assays was evaluated for statistical
significance using Student's t-test. Differences in the values
were considered significant at p b 0.5.Extraction of nuclear and cytosolic fractions
Active Motif Nuclear Extraction Kit (Carlsbad, CA) was used
to isolate the cytoplasmic and nuclear fractions from the
cells as per the manufacturer's instructions. Briefly, 1× PBS
washed cell pellets were resuspended in appropriate amount
of hypotonic buffer and incubated at 4 °C on a rocking
platform for 30 min and then centrifuged at 14,000 ×g for
30 s. The supernatant was collected and represented as
cytosolic fraction. The remaining pellets were resuspended
in complete lysis buffer and incubated at 4 °C for 30 min on
a rocking platform. The suspension was then homogenized
and the nuclear fractions were collected after centrifuga-
tion at 14,000 ×g for 10 min. Immunoblot analysis for JNK
and p-JNK was performed with the cytosolic and nuclear
fractions.Immunocytochemical analysis
Glioma cells grown in 4-well chamber slides (Nalgene Nunc
International, Naperville, IL) were fixed with 4% buffered
formalin for 1 h at room temperature, washed, and treated
with 0.1% Triton X-100 before labeling with p-JNK and
p-Paxillin primary antibodies at 4 °C overnight. The cells
were then stained with Alexa Fluor-conjugated secondary
antibodies for 1 h at room temperature, nuclear stained
with DAPI, and visualized under a confocal microscope.
Immunohistochemical analysis
Stereotactic implantation of 5310 and 4910 non-GICs and
GICs was carried out as described previously (Lakka et al.,
2004). Mice were treated with mock, pUC, 10 Gy, and
pUC + 10 Gy using ALZET mini-osmotic pumps at the rate
of 0.25 μL/h. After 5 weeks, the mice were killed by
intracardiac perfusion, first with PBS and then with 4%
paraformaldehyde in normal saline. Paraffin sections were
prepared.
For co-localization studies, the deparaffinized sections were
antigen retrieved and incubated overnight with p-Paxillin
and p-JNK primary antibodies at 4 °C in a humidified chamber.
They were then stained with the Alexa Fluor conjugated
secondary antibodies for 1 h in the dark at room temperature,
and nuclear stained with DAPI for a brief period of time before
mounting. The sections were then pictured under a confocal
microscope.
Results
pUC treatment decreased the radiation-induced
expression of uPAR and cathepsin B
Radiation remains one of the essential therapies for treating
cancer patients. To observe the effect of radiation treat-
ment on the expression levels of uPAR and cathepsin B, 5310
and 4910 glioma cells were treated with 5 and 10 Gy at 24 h
and 48 h. Radiation-treated 5310 and 4910 non-GICs and
GICs showed an increase in the expression levels of uPAR
and cathepsin B when compared to their controls (data not
shown). Non-GICs responded to radiation treatment within
24 h whereas the response from GICs was significant only after
48 h of radiation treatment, indicating the radioresistance of
GICs. Based on these results, non-GICs were treated with
10 Gy for 24 h andGICswere treatedwith 10 Gy for 48 h in the
subsequent experiments.
An effective inhibition of uPAR and cathepsin B expres-
sion in pUC and pUC + 10 Gy treated 5310 and 4910 non-GICs
and GICs in comparison to their respective non-radiated and
radiated controls at 72 h was confirmed by western blotting
as shown in Supplementary Fig. 1.
uPAR and cathepsin B knockdown inhibited
migration of the glioma xenograft cells
Migration of individual cells from the primary tumor mass is
considered to be an essential and initial step for attaining an
invasive and metastatic cancer phenotype (Friedl and Wolf,
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the migrating potentials of 5310 and 4910 non-GICs and GICs
with pUC and radiation alone or in combination. The xenograft
cells from SV-radiated spheroids migrated more (81.32% —
5310 non-GICs, 54.56% — 5310 GICs, 64.54% — 4910 non-GICs,
and 18.1% — 4910 GICs) when compared to that of their SV-
treated spheroids (Figs. 1A & B). A prominent reduction in the
migration of the cells from spheroids was noticed upon
treatment with pUC (69.45% — 5310 non-GICs, 47.97% — 5310
GICs, 66.58% — 4910 non-GICs and 49.74% — 4910 GICs) and
pUC + 10 Gy (60.96% — 5310 non-GICs, 38.27% — 5310 GICs,
59.21% — 4910 non-GICs, and 28.79% — 4910 GICs) when
compared to the cells migrating from SV-treated and SV-
radiated spheroids, respectively.Figure 1 Effect of radiation, pUC, and inhibitor treatment on mig
and 4910 non-GICs and GICs were treated with SV, pUC, 10 Gy, an
spheroids, radiation treatment was given for 24 h, and for GIC sphero
then allowed to migrate for another 24 h, Hema stained and pictur
spheroids was measured using a microscope calibrated with a microm
average migration obtained from 3 independent experiments. C) 53
inhibitor (10 μM U0126), JNK inhibitor (10 μM SP600125) and p38
another 24 h. The spheroids were then fixed with methanol, Hema
migration into monolayers was quantified with a microscope calibra
migration obtained from 3 independent experiments; *, p b 0.5 andMAPK inhibition reduced cell migration
Many extracellular signals converge at a family of serine/
threonine protein kinases called MAPKs. Based on the differ-
ences in the motifs within their activation loops, they can
be divided into 3 groups: ERK, JNK and p38. MAPKs play well-
known roles in cell proliferation, oncogenesis, differentiation,
inflammation and stress response, but accumulating evidence
indicates that this family is also essential for cell migration
(Huang et al., 2004b). Hence, we hypothesized that MAPKs
might play a role in regulating the migration of 5310 and 4910
glioma xenograft cells.
Spheroid migration assay revealed that the cells migrating
from the spheroids treated with MAPK inhibitors displayed aration of 5310 and 4910 non-GICs and GICs. A) Spheroids of 5310
d pUC + 10 Gy. pUC treatment was given for 72 h. For non-GIC
ids, radiation treatment was given for 48 h. The spheroids were
ed under a light microscope. B) Migration of the cells from the
eter and percent migration was calculated from the mean of the
10 and 4910 non-GIC and GIC spheroids were treated with ERK
inhibitor (10 μM SB20219) for 24 h and allowed to migrate for
stained and visualized under a light microscope. D) Spheroid
ted with a micrometer and calculated as a mean of the average
**, p b 0.01. Bar = 500 μm.
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treated spheroids (Figs. 1C & D). ERK inhibitor (U0126)
induced 69.9%, 53.6%, 63.7% and 46.6% reduction, JNK
inhibitor (SP600125) induced 65.1%, 46.1%, 60.1% and 39.5%
reduction, and p38 inhibitor (SB202190) induced 32.3%, 18.1%,
24.5% and 11.1% reduction in the migration of the cells
from 5310 non-GIC, 5310 GIC, 4910 non-GIC, and 4910 GIC
spheroids, respectively when compared to their DMSO control
spheroids. Quantification of migration of the cells from
spheroids thus revealed that ERK and JNK inhibitors were
very effective when compared to that of the p38 inhibitor.
Thus, we continued our further studies with ERK and JNK.
Simultaneous knockdown of uPAR and cathepsin B
increased the expression of p-JNK
To observe the involvement of uPAR and cathepsin B in
regulating the migration of the glioma cells through ERK and
JNK, western blot analysis of 5310 and 4910 non-GICs and
GICs was conducted after transfecting the cells with the
bicistronic construct. pUC-treated non-GICs and GICs alone
or in combination with radiation showed a decrease in the
expression of p-ERK and an increase in the expression of p-JNK
(Fig. 2). Earlier we observed that JNK inhibitor significantly
reduced the migration of the cells (Figs. 1C and D); however,Figure 2 pUC treatment alone or in combination with radiation
extracted and western blot analyses of A) 5310 non-GICs, B) 5310 G
p-ERK, JNK and p-JNK antibodies. GAPDH served as a loading controa significant increase in the protein expression of p-JNK
was noticed with pUC and pUC + 10 Gy treatments. Since
the above results seemed to be contradictory, we further
concentrated on the role of uPAR and cathepsin B in regulating
the JNK–MAPK pathway.pUC treatment induced the translocation of p-JNK
into the nucleus
Since, compartment-specific signaling of JNK has been
reported earlier (Bogoyevitch and Kobe, 2006), we investigated
the variations in the localization of p-JNK by isolating
the nuclear and cytosolic extracts from pUC-treated glioma
xenograft cells. Investigation of cytosolic and nuclear extracts
from the cells treated with pUC, 10 Gy and their combination
revealed a profound increase in the nuclear localization of
activated JNK in the cells treated with pUC and pUC + 10 Gy
(Fig. 3A). Nuclear localization of a minor pool of p-JNK was
noticed in the glioma cells treated with radiation when
compared to that of their non-irradiated controls. It was also
noted that the nuclear translocation of p-JNK was more in the
irradiated non-GICs when compared to that of the irradiated
GICs. Nuclear localization of p-JNK in non-GICs and GICs treated
with pUC alone or in combination with radiation was furtherdownregulated p-ERK and upregulated p-JNK. Cell lysates were
IC, C) 4910 non-GIC and D) 4910 GIC were performed for ERK,
l.
Figure 3 pUC treatment alone or in combination with radiation induced the translocation of p-JNK into the nucleus of 5310 and
4910 glioma cells. A) Cytosolic and nuclear fractions of 5310 and 4910 non-GICs and GICs treated with pUC and radiation alone or in
combination were isolated. Western blot analyses of cytosolic and nuclear fractions of non-GICs and GICs were performed and
immunoblotted for JNK and p-JNK. GAPDH served as a loading control for cytosolic fractions and laminin served as a loading control
for nuclear fractions. B) 5310 and 4910 non-GICs and GICs were grown in 4-well chamber slides, treated for 72 h, fixed with buffered
formalin, incubated with p-JNK, stained with Alexa Fluor-conjugated secondary antibodies, nuclear stained with DAPI, and pictured
under a confocal microscope. Bar = 200 μm. C) 5310 and 4910 glioma xenograft cells were treated with full-length uPAR (FLU) and
full-length cathepsin B (FLC) plasmids for 48 h. Total extracts were immunoblotted for uPAR and cathepsin B. Cytosolic and nuclear
extracts were isolated and western blotted for JNK and p-JNK. GAPDH served as the cytosolic loading control and laminin served as
the nuclear loading control.
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Fig. 3B.
To observe the effect of upregulation of uPAR and cathepsin
B on the activation and translocation of JNK, cytosolic and
nuclear extracts from the cells transfected with FLU and FLC
plasmids were isolated and immunoblotted for p-JNK. An
increase in the cytosolic expression of p-JNK was observed in
5310 and 4910 non-GICs and GICs while the expression levels of
p-JNK in the nuclear extracts of FLU- and FLC-treated glioma
cells remained unchanged (Fig. 3C). Further, it was also
observed that the FLU- and FLC-treated spheroids migrated
more compared to that of their control spheroids (Supple-
mentary Fig. 2), indicating that the cytoplasmic pool of p-JNK
might be driving the cells towards a migratory phenotype.Depletion of cytosolic p-JNK by downregulating
uPAR and cathepsin B reduced the expression of
focal adhesion molecules
Recent findings indicate that several targets of the JNK
signaling pathway include a number of focal adhesion,
microtubule-associated and intermediate filament proteins
that are involved in cell migration (Bogoyevitch and Kobe,
2006; Huang et al., 2004b). In our study, we observed that
the protein levels of themigratorymotormolecules p-Paxillin,
Vinculin, α-Actinin and Talin (Fig. 4a) and the adhesion
molecules Integrin αvβ3 and Integrin β1 (Supplementary
Fig. 5) also increased with radiation as compared to their
matched non-irradiated counterparts. pUC treatment
Figure 4 Cytosolic p-JNK aided in the migration of 5310 and 4910 non-GICs and GICs. A) 5310 and 4910 non-GICs and GICs were
treated with pUC and 10 Gy radiation alone or in combination. Cell lysates were isolated and western blotted for Paxillin, p-Paxillin,
Vinculin, α-Actinin and Talin. GAPDH served as a loading control. B) 5310 and 4910 xenograft cells were treated with SV, DMSO,
10 Gy, FLU and FLC alone and in combination with JNK inhibitor (10 μM SP600125 represented as SP). Cell lysates were isolated and
western blotted for JNK, p-JNK, Paxillin, p-Paxillin, Vinculin, α-Actinin and Talin. GAPDH served as a loading control.
722 K. Alapati et al.induced the translocation of p-JNK into the nucleus and
therefore reduced the availability of cytosolic p-JNK in the
cells treated with pUC and pUC + 10 Gy. Western blot analysis
of 5310 and 4910 non-GICs and GICs revealed that the
depletion of cytosolic p-JNK in the cells treated with pUC
alone or in combination with radiation reduced the expression
levels of the aforementioned migratory motor molecules
(Fig. 4A) and the adhesion molecules (Supplementary Fig. 5).
Addition of JNK inhibitor SP600125 to cells treated with SV,
DMSO, 10 Gy, FLU and FLC significantly decreased the protein
expression levels of p-Paxillin, Vinculin, α-Actinin, and Talin
when compared to that of their respective counterparts
(Fig. 4B), indicating the importance of cytosolic p-JNK in
regulating the migration of the cells.
Downregulation of uPAR and cathepsin B reduced the
interaction of p-JNK with migratory motor molecules
A direct interaction between p-JNK and p-Paxillin, Vinculin
andα-Actininwas observed in the immunoprecipitated control
samples of 5310 and 4910 non-GICs and GICs (Fig. 5A).
This interaction was further augmented in the cells treated
with radiation against their non-irradiated counterparts
(Fig. 5A). When non-GICs and GICs were treated with pUC
and pUC + 10 Gy, a significant reduction in the precipitation
of p-Paxillin, Vinculin and α-Actinin with p-JNK was evidentwhen compared to that of their SV-treated and SV-irradiated
controls, respectively (Fig. 5A). Immunocytochemical analysis
also confirmed the co-localization of p-JNK with p-Paxillin at
the leading edge of themigrating SV-treated and SV-irradiated
non-GICs and GICs (Supplementary Fig. 3). It is noteworthy
that the pUC and pUC + 10 Gy treated cells displayed an
increase in the expression of nuclear p-JNK and a decrease in
the expression of p-Paxillin and its co-localization with p-JNK.
In accordance with the in vitro studies, p-JNK and
p-Paxillin significantly co-localized in the tissue sections of
the mice implanted with glioma xenograft cells (Fig. 5B). The
interaction between p-JNK and p-Paxillin further increased in
the irradiated tissue sections. pUC treatment alone or in
combination with radiation efficiently inhibited the interac-
tion between p-JNK and p-Paxillin. Nuclear localization of
p-JNK in the tissue sections of mice treated with pUC and
pUC + 10 Gy was also evident.
uPAR and cathepsin B regulate p-JNK through
Ras–PI3K pathway
Alterations in Ras–MAPK pathway have been reported
to play critical roles in tumorigenesis by regulating the
proliferation, differentiation and migration of the tumor
cells (Santarpia et al., 2012). Based on this earlier report,
we conducted the western blot analysis of 5310 and 4910
Figure 5 p-JNK interacted with the migratory motor molecules. A) 5310 and 4910 non-GICs and GICs were treated with pUC and
radiation alone or in combination. The cell lysates were collected and immunoprecipitated for p-JNK antibody and then western
blotted for p-JNK, α-Actinin, Vinculin and p-Paxillin. B) 5310 and 4910 non-GICs and GICs were implanted intracranially and treated
with mock, pUC, and radiation alone or in combination. When chronic symptoms were observed, mice were sacrificed and their brains
were removed and embedded in paraffin. Deparaffinized sections were incubated with p-JNK (red) and p-Paxillin (green), stained
with Alexa Fluor-conjugated secondary antibodies, and nuclear stainedwith DAPI. The sections were then visualized for co-localization of
p-JNK and p-Paxillin under a confocal microscope. Arrows indicate the enlarged inset pictures. Bar = 50 μm.
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expression levels of Ras, p-PI3K, Rac-1 and p-Pak-1 in the cells
treated with pUC alone or in combination with radiation when
compared to that of their controls (Supplementary Fig. 4).
Irradiated non-GICs and GICs displayed an increase in the
protein levels of the above mentioned Ras-pathway moleculesagainst their non-irradiated counterparts. An increase in
the expression of MEKK-1 was observed in the non-GICs and
GICs treated with pUC, radiation and their combination when
compared to the controls.
A bulk of p-JNK co-immunoprecipitated with MEKK-1 in the
pUC-treated 5310 and 4910 xenograft cells (Fig. 6A). Some
Figure 6 uPAR and cathepsin B regulated the translocation of p-JNK through Ras signaling. A) Cell lysates from 5310 and 4910
xenograft cells treated with SV, pUC, 10 Gy, FLU and FLC were isolated. The cell lysates were used for SDS-PAGE and immunoblotted
for Pak-1, p-Pak-1, MEKK-1, JNK and p-JNK. GAPDH served as a loading control. B) Cell lysates of 5310 and 4910 non-GICs and GICs
treated with SV, pUC, 10 Gy, FLU and FLC were used for immunoprecipitation analysis with p-JNK antibody and then western blotted
for MEKK-1. IgG served as a loading control. C) 5310 and 4910 glioma cells were treated with DMSO and Pak-1 inhibitor (10 μM IPA3),
and their cell lysates were extracted. Their lysates were western blotted for Pak-1, p-Pak-1, MEKK-1, JNK and p-JNK. GAPDH served
as a loading control. D) Cell lysates of the glioma xenograft cells treated with DMSO and IPA3 were immunoprecipitated with p-JNK
antibody and then western blotted for MEKK-1.
724 K. Alapati et al.amount of interaction between p-JNK and MEKK-1 was also
observed in the cells treated with irradiation whereas the
control cells and the cells treated with FLU and FLC did not
display any interaction between p-JNK and MEKK-1 (Fig. 6B). It
was also observed that the Pak-1 inhibitor IPA3 did not induceFigure 7 Wortmannin was ineffective on pUC-induced expression
non-GIC, and D) 4910 GIC cells were treated with pUC, 10 Gy, and PI
combination. Cell lysates were isolated and western blotted for PI3
GAPDH served as a loading control.any effect on the expression of p-JNK and MEKK-1 (Fig. 6C).
However, treating 5310 and 4910 non-GICs and GICs with Pak-1
inhibitor (IPA3) induced the co-immunoprecipitation of p-JNK
with MEKK-1 while the control cells displayed no interaction
between these molecules (Fig. 6D). This indicates that pUCof p-JNK and MEKK-1. A) 5310 non-GIC, B) 5310 GIC, C) 4910
3K inhibitor (10 μM Wortmannin represented as Wort) alone or in
K, p-PI3K, Ras, Rac-1, Pak-1, p-Pak-1, MEKK-1, JNK and p-JNK.
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Figure 8 uPAR and Cathepsin B mediated migration of glioma cells.
726 K. Alapati et al.treatment inhibits the function of p-Pak-1 and thereby induces
the formation MEKK-1–p-JNK complex formation and the
translocation of this complex into the nucleus of the pUC-
treated cells.
Nuclear translocation of MEKK-1–p-JNK
complex nullifies the effect of PI3K inhibitor
To further confirm the regulation of p-JNK by uPAR and
cathepsin B through the Ras–Pak-1 pathway, we treated
the glioma xenograft cells with PI3K inhibitor Wortmannin
(Wort). 5310 and 4910 non-GICs and GICs treated with Wort
and 10 Gy + Wort showed a decrease in the protein levels of
p-PI3K, Rac-1, p-Pak-1, MEKK-1 and p-JNK when compared
to that of the SV/DMSO treated cells and 10 Gy irradiated
cells, respectively (Fig. 7). A decrease in the expression of
p-PI3K, Rac-1 and p-Pak-1 was observed in pUC + Wort treated
5310 and 4910 cells while therewas no effect on the expression
of p-JNK and MEKK-1 when compared to pUC-treated cells.Discussion
Malignant gliomas are extremely lethal and have a 5-year
survival rate of less than 3%. Despite aggressive clinical
treatment including surgical resection, radiation and chemo-
therapy, tumor recurrence is essentially universal (Lathia et
al., 2011; Stupp et al., 2005). Failure of these regimens mightbe attributed to the highly infiltrative nature of the glioma
cells that reside in the normal brain at distant locations from
the origin of the tumor. Also, the existence of highly resistant,
self-replicating glioma-initiating cells (GICs) decreases the
success of existing treatment strategies. Approaches that
target the invasive capacity of glioma cells as well as the
proliferative nature of GICs may significantly improve thera-
peutic outcomes.
We have previously demonstrated the isolation and
characterization of GICs from established cell lines (Alapati
et al., 2012; Malla et al., 2012a); we used 5310 and 4910
GICs for the present study. Radiotherapy is a key treatment
modality for treating patients with intracranial tumors, but its
efficacy is limited by radioresistance and by the promotion of
malignant behavior of the cancer cells (Kang et al., 2012; Kil
et al., 2012). In our present study, radiation treatment
increased the migration of the glioma cells as well as the
expression of uPAR and cathepsin B. Elevated levels of uPAR
and cathepsin B have been strongly correlated with tumor
invasiveness (Besch et al., 2007; Levicar et al., 2003; Rao,
2003; Sevenich et al., 2011), indicating that the cells treated
with radiation were adapting towards an aggressive invasive
phenotype.
The three core protein kinases of the MAPK family are
capable of responding to a number of stimuli to produce
specific cellular outcomes. In particular, the precise nature
of the extracellular stimuli and the repertoire of molecules
available in each cell type can determine the localization,
timing, intensity and duration of the activation of each
727Compartmentalization of JNK Regulates Glioma Migrationmember of the MAPK family (Raman et al., 2007; Turjanski
et al., 2007). Several reports indicate the involvement of
MAPKs in gene expression, proliferation, motility, metabolism
and apoptosis (Cuevas et al., 2007; Dhillon et al., 2007; Huang
et al., 2004b; Qi and Elion, 2005). Here, we studied the
regulation of glioma cell migration by uPAR and cathepsin B
via the MAPK pathway.
In our study, ERK and JNK inhibitors effectively inhibited
the migration of glioma cells while the effect of the p38
inhibitor was not as significant. Hence, we further evaluat-
ed the effect of downregulation of uPAR and cathepsin B on
the expression of ERK and JNK. Reduction in the expression
levels of p-ERKwith pUC and pUC + 10 Gy and the inhibition of
migration of the cells with ERK inhibitor indicated that the
activation of ERK is necessary for cell migration (Lind et al.,
2006; Nguyen et al., 1999). shRNA treatment and the inhibitor
treatment with respect to the activation of JNK and migration
of glioma cells seemed to be contradictory. These phenomena
prompted us to further concentrate on the involvement of JNK
in the migration of glioma cells.
Based on the stimuli, compartment-specific localization
and activation of JNK have been demonstrated in several
earlier reports (Bjorkblom et al., 2008; Coffey et al., 2000).
In our study, pUC treatment alone and in combination with
radiation induced the activation and translocation of JNK
into the nucleus of non-GICs and GICs. Even though a minor
pool of nuclear activity existed in the irradiated cells, the
majority of p-JNK remained in their cytoplasmic compart-
ments. This means that the pUC-induced translocation of
p-JNK into the nucleus might impair its ability to influence
the migration of cells. Overexpressing uPAR and cathepsin B
by transfecting the cells with FLU and FLC induced an
increase in the accumulation of p-JNK in the cytoplasm of
the cells. Overexpression of uPAR and cathepsin B did not
show any effect on the nuclear pools of p-JNK. Also an
increase in the migration of the glioma non-GICs and GICs
was observed after FLU and FLC treatments. Taken together,
these results further provide evidence that uPAR and cathepsin
B-mediated activation of cytoplasmic JNK is required for the
migration of the cells whereas the nuclear pool of active JNK
cannot impact migration. Previously, it was reported that the
activation of cytoplasmic pool of JNK was required for the
migration of NRK cells (Rosse et al., 2009) and dendritic cells
(Bjorkblom et al., 2005).
The dynamic assembly and disassembly of focal adhe-
sions play central roles in cell migration. Adapter proteins
such as Paxillin, Vinculin, α-Actinin and Talin are very
important for the formation of these focal adhesion
complexes at the leading edge of the migrating cell
(Huttenlocher and Horwitz, 2011; Vicente-Manzanares et
al., 2009). In our present study, the non-GICs and GICs
treated with pUC and pUC + 10 Gy showed a significant
decrease in the expression of the adhesion machinery
molecules p-Paxillin, Vinculin, α-Actinin, Talin, Integrin
αvβ3 and Integrin β1. Along with various well-known
transcription factors and apoptosis-related proteins that
are substrates for JNK, several cytoskeleton-associated
proteins and signaling molecules as well as adaptor proteins
have recently been identified (Bogoyevitch and Kobe, 2006;
Huang et al., 2004b). Radiation, FLU and FLC treatments
increased the expression of the above mentioned adhesion
molecules, which were inhibited by treating the cells withthe JNK inhibitor. This result further confirms that uPAR and
cathepsin B regulate the migration and adhesion of glioma
cells through the activation of cytoplasmic JNK.
Localized activation of JNK at the leading edge of migrating
NRK cells (Rosse et al., 2009) and the localization of JNK to the
actin dense membrane ruffles of the migrating fibroblast cells
(Amagasaki et al., 2006) were observed earlier. In our present
study, p-JNK interacted with p-Paxillin at the leading edge
of the migrating glioma cells. Along with p-Paxillin, p-JNK
directly interactedwith Vinculin as well asα-Actinin. The direct
interaction between these molecules was inhibited by treating
the cells with pUC alone or in combination with radiation. This
further provides evidence for uPAR and cathepsin B-mediated
regulation of p-JNK and its interaction with the focal adhesion
molecules required for glioma cell migration. Inhibition of
co-localization of p-JNK and p-Paxillin was also evident in the in
vivo sections treated with pUC alone or in combination with
radiation and led to the regression of tumor growth.
Ras–MAPK signaling is often deregulated and is constitutive-
ly active in many types of cancers including pancreatic, colon,
lung, melanoma and breast (Dunn et al., 2005). Activation of
PI3K, Rac-1 and JNK was necessary for bFGF-induced fibroblast
migration and blocking the activation of PI3K, Rac-1 or JNK has
been shown to significantly downregulate the wound healing
capacity of these cells (Kanazawa et al., 2010). PI3K–Rac-1–
JNK signaling was for collagen I-induced fibroblastic transfor-
mation and scattering of NMuMG mammary epithelial cells
(Shintani et al., 2006). Further, the cytoplasmic accumulation
of JNK activated by constitutively active Rac-1 has been
demonstrated in intestinal epithelial cells (Stappenbeck
and Gordon, 2001). Taken together, these reports suggest
the involvement of Ras–PI3K signaling in regulating the
activation of JNK. In our present study, the upstream signal
required for the activation and accumulation of cytoplasmic
JNK appears to involve Ras–PI3K–Rac-1–Pak-1 pathway as
evidenced by the upregulation of these molecules in the
cells treated with radiation. Further, cells treated with pUC
and pUC + 10 Gy showed a decrease in the expression of these
molecules, indicating that uPAR and cathepsin B regulate the
Ras–Pak-1 pathway. Inhibition of Ras–Pak-1 pathway by pUC
treatment, alone or in combination with radiation, led to an
increase in the expression of MEKK-1.
MEKK-1 interacted with p-JNK in the cells treated with pUC
and to some extent in the cells treatedwith 10 Gy. In contrast,
there was no interaction between these molecules in the cells
treated with SV, FLU or FLC.We have previously reported that
apoptosis was induced in glioma cells treated with pUC (Malla
et al., 2010, 2012b) and to some extent in glioma cells treated
with radiation (Malla et al., 2012a). Hence, it is possible that
these molecules are interacting only in the cells that are
undergoing apoptosis. An increase in the interaction between
MEKK-1 and p-JNK was also observed in the cells treated with
the Pak-1 inhibitor (IPA3). Further, we observed that the
expression of MEKK-1 and p-JNK remained unaltered with the
Pak-1 inhibitor. As per the above findings, it can be considered
that Pak-1 negatively regulates the binding of MEKK-1 with
p-JNK. A similar kind of Pak-1-mediated negative regulation
of MEKK-1-dependent JNK pathway was observed in 293
human embryonic kidney cells (Gallagher et al., 2002). Pak-1
constitutively phosphorylates MEKK-1 on serine 67 in resting
293 cells, but its dephosphorylation following exposure to
anisomycin allows the binding of JNK to MEKK-1.
728 K. Alapati et al.To further confirm that uPAR and cathepsin B were
regulating the activation of JNK through the Ras–Pak-1
pathway, cells were treated withWortmannin, a PI3K inhibitor.
It is noteworthy thatWortmannin did not show any effect on the
expression of MEKK-1 and p-JNK in pUC-treated cells while a
decrease in the expression of these molecules was observed in
the non-irradiated and irradiated control cells treated with
Wortmannin. This might be due to the translocation of the
MEKK-1–p-JNK complex into the nucleus of pUC-treated
non-GICs and GICs. These results further confirm that the
translocation of activated JNK is regulated through the Ras–
PI3K pathway.
In conclusion, uPAR and cathepsin B mediate the
migration of glioma cells by increasing the localization of
cytoplasmic JNK at the focal complexes of the leading edge
of glioma cells as depicted in Fig. 8. uPAR and cathepsin B
regulate the Ras–Pak-1 pathway by controlling the activa-
tion and translocation of JNK. shRNA treatment against
uPAR and cathepsin B inhibits the Ras–Pak-1 pathway,
thereby inducing the activation and interaction of MEKK-1
with p-JNK. The MEKK-1 and p-JNK complex further translo-
cates into the nucleus, reducing the availability of the
cytoplasmic pool of JNK required for the migration of the
glioma cells. Taken together, it can be concluded that the
cytosolic activity of JNK induces the migration of cells and
radiation further enhances this phenomenon, thereby driving
these glioma cells towards a more malignant and resistant
phenotype. pUC treatment induces nuclear translocation of
p-JNK and thus reduces the migration of 5310 and 4910
non-GICs and GICs. Finally, it can be concluded that the
regulation of JNK–MAPK through the simultaneous suppression
of uPAR and cathepsin B proves to be a potential therapeutic
target for inhibiting the migration of glioma cells.
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